Skip to main content

Building

A better future

through education, skill development and research

LEARN MORE

Combination Drug Therapy Effectively Treats Male Infertility

Two drugs that are commonly used off-label in the treatment of male infertility are clomiphene citrate (CC) and anastrozole (AZ); however, data are lacking on the use of combination CC+AZ therapy.

Wednesday, June 6, 2018 12:01 am EDT

Two drugs that are commonly used off-label in the treatment of male infertility are clomiphene citrate (CC) and anastrozole (AZ); however, data are lacking on the use of combination CC+AZ therapy. A new BJU International study found that combination CC+AZ therapy is safe and effective for patients with elevated estradiol or a low testosterone/estradiol ratio.


In the study of 51 men, AZ provided an effective means for lowering estradiol levels and increasing the testosterone/estradiol ratio following the initiation of CC therapy. CC is a selective estrogen receptor modulator that increases gonadotropin production and indirectly stimulates androgen synthesis, but it is associated with increased estradiol levels. AZ is an aromatase inhibitor that decreases conversion of testosterone to estradiol.

Additional Information

Link to Study: https://physoc.onlinelibrary.wiley.com/doi/10.1111/bju.14390

About Journal

BJUI aims to provide the very highest standard of research and clinical information for the urological community, promoting awareness of new advances and supporting best practice in urology.

BJUI publishes original articles, reviews, comments and educational articles on adult and paediatric urology. Clinical relevance is critical and the journal covers the entire breadth of urology under the following sections: Comments, Reviews, Urological Oncology (all areas of urological oncology as well as recent advances in diagnostic techniques), Robotics and Laparoscopy, Upper Urinary Tract, Functional Urology, Sexual Medicine, Paediatrics, Translational Science, Surgical Education and Step-by-Step.

BJUI is constantly innovating to provide the urology community with a journal that is fresh in appearance and easy to read. The journal is divided into sections and in full colour making it easier to read, and is presented with additional features and supporting discussions on our website: www.bjui.org.

Accompanying BJUI are regular supplements on topics of current interest in urology.

Multimedia Files:

Preview image

Contact:

Josh Glickman
+1 201-748-6572
sciencenewsroom@wiley.com

Business Wire NewsHQsm